164 related articles for article (PubMed ID: 36375974)
1. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
Okumura S; Ishihara M; Kiyota N; Yakushijin K; Takada K; Kobayashi S; Ikeda H; Endo M; Kato K; Kitano S; Matsumine A; Nagata Y; Kageyama S; Shiraishi T; Yamada T; Horibe K; Takesako K; Miwa H; Watanabe T; Miyahara Y; Shiku H
BMJ Open; 2022 Nov; 12(11):e065109. PubMed ID: 36375974
[TBL] [Abstract][Full Text] [Related]
2. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
3. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
Creemers JHA; Pawlitzky I; Grosios K; Gileadi U; Middleton MR; Gerritsen WR; Mehra N; Rivoltini L; Walters I; Figdor CG; Ottevanger PB; de Vries IJM
BMJ Open; 2021 Nov; 11(11):e050725. PubMed ID: 34848513
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4
Wang L; Matsumoto M; Akahori Y; Seo N; Shirakura K; Kato T; Katsumoto Y; Miyahara Y; Shiku H
Mol Ther; 2024 Mar; 32(3):734-748. PubMed ID: 38243600
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10
Blumenschein GR; Devarakonda S; Johnson M; Moreno V; Gainor J; Edelman MJ; Heymach JV; Govindan R; Bachier C; Doger de Spéville B; Frigault MJ; Olszanski AJ; Lam VK; Hyland N; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou D; Pentony MM; Sanderson JP; Gerry A; Marks D; Bai J; Holdich T; Norry E; Fracasso PM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086946
[TBL] [Abstract][Full Text] [Related]
6. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.
Lonez C; Verma B; Hendlisz A; Aftimos P; Awada A; Van Den Neste E; Catala G; Machiels JH; Piette F; Brayer JB; Sallman DA; Kerre T; Odunsi K; Davila ML; Gilham DE; Lehmann FF
BMJ Open; 2017 Nov; 7(11):e017075. PubMed ID: 29133316
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
[TBL] [Abstract][Full Text] [Related]
11. Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial.
Wang L; Tang J; Chen X; Zhao J; Tang W; Liao B; Nian W
BMJ Open; 2022 Jun; 12(6):e055742. PubMed ID: 35688598
[TBL] [Abstract][Full Text] [Related]
12. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial.
Voskens CJ; Stoica D; Roessner S; Vitali F; Zundler S; Rosenberg M; Wiesinger M; Wunder J; Siegmund B; Schuler-Thurner B; Schuler G; Berking C; Atreya R; Neurath MF
BMJ Open; 2021 Dec; 11(12):e049208. PubMed ID: 34880013
[TBL] [Abstract][Full Text] [Related]
15. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
16. Autologous T cell therapy for MAGE-A4
Hong DS; Van Tine BA; Biswas S; McAlpine C; Johnson ML; Olszanski AJ; Clarke JM; Araujo D; Blumenschein GR; Kebriaei P; Lin Q; Tipping AJ; Sanderson JP; Wang R; Trivedi T; Annareddy T; Bai J; Rafail S; Sun A; Fernandes L; Navenot JM; Bushman FD; Everett JK; Karadeniz D; Broad R; Isabelle M; Naidoo R; Bath N; Betts G; Wolchinsky Z; Batrakou DG; Van Winkle E; Elefant E; Ghobadi A; Cashen A; Grand'Maison A; McCarthy P; Fracasso PM; Norry E; Williams D; Druta M; Liebner DA; Odunsi K; Butler MO
Nat Med; 2023 Jan; 29(1):104-114. PubMed ID: 36624315
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Hong DS; Butler MO; Pachynski RK; Sullivan R; Kebriaei P; Boross-Harmer S; Ghobadi A; Frigault MJ; Dumbrava EE; Sauer A; Brophy F; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou DG; Wang R; Solis LM; Duose DY; Sanderson JP; Gerry AB; Marks D; Bai J; Norry E; Fracasso PM
Front Oncol; 2022; 12():818679. PubMed ID: 35372008
[TBL] [Abstract][Full Text] [Related]
18. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
19. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
